Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of "Buy" by Brokerages

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) have earned a consensus rating of "Buy" from the ten brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $63.33.

Several brokerages have recently commented on VERA. JPMorgan Chase & Co. decreased their price objective on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a report on Tuesday, March 4th. Guggenheim increased their price target on Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Wolfe Research began coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price target on the stock. HC Wainwright initiated coverage on Vera Therapeutics in a research report on Monday, May 5th. They set a "buy" rating and a $75.00 target price on the stock. Finally, The Goldman Sachs Group began coverage on shares of Vera Therapeutics in a research note on Tuesday, January 28th. They set a "buy" rating and a $58.00 target price for the company.

Vera Therapeutics Trading Down 3.1%

Shares of NASDAQ VERA traded down $0.60 during trading hours on Monday, reaching $19.04. The stock had a trading volume of 1,724,547 shares, compared to its average volume of 786,155. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -7.30 and a beta of 1.28. The business's fifty day moving average price is $22.58 and its two-hundred day moving average price is $32.79. Vera Therapeutics has a 52-week low of $18.53 and a 52-week high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same period in the prior year, the firm posted ($0.56) earnings per share. Analysts expect that Vera Therapeutics will post -2.89 EPS for the current fiscal year.

Institutional Trading of Vera Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Huntington National Bank acquired a new stake in shares of Vera Therapeutics during the 4th quarter worth approximately $26,000. AlphaQuest LLC acquired a new stake in shares of Vera Therapeutics during the 4th quarter worth approximately $34,000. GF Fund Management CO. LTD. acquired a new stake in shares of Vera Therapeutics during the 4th quarter worth approximately $56,000. Quarry LP increased its holdings in shares of Vera Therapeutics by 25.0% during the 1st quarter. Quarry LP now owns 2,500 shares of the company's stock worth $60,000 after buying an additional 500 shares during the last quarter. Finally, KBC Group NV increased its holdings in shares of Vera Therapeutics by 127.2% during the 4th quarter. KBC Group NV now owns 2,477 shares of the company's stock worth $105,000 after buying an additional 1,387 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company's stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.